Related references
Note: Only part of the references are listed.Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Trends in COVID-19 therapeutic clinical trials
Kevin Bugin et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Poor trials of health steps are worse than none, scientists say
Cathleen O’Grady
SCIENCE (2021)
Understanding the use of observational and randomized data in cardiovascular medicine
Louise Bowman et al.
EUROPEAN HEART JOURNAL (2020)
Real World Data as Trial End Points Off and Running With a Long Way to Go
Marvin A. Konstam
CIRCULATION (2020)
Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
Theo Vos et al.
LANCET (2020)
EuroHeart: European Unified Registries On Heart Care Evaluation and Randomized Trials
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2019)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Thrombus Aspiration during ST-Segment Elevation Myocardial Infarction
Ole Frobert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sensible approaches for reducing clinical trial costs
Eric L. Eisenstein et al.
CLINICAL TRIALS (2008)
Clinical trials bureaucracy: unintended consequences of well-intentioned policy
Robert M. Califf
CLINICAL TRIALS (2006)
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
C Baigent et al.
LANCET (2005)
Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials
R Collins et al.
LANCET (2001)
Share Paper
